Emerging trends, confront and scenario in healthcare and antiviral development for infectious diseases

作者: Mishra N

DOI:

关键词:

摘要: Health defines the state of being free from illness, infection or injury and healthcare performs diagnosis, treatment prevention such anomalies. Infectious diseases are well known since ancient time to human civilization put heavy toll on social health as system. Among different infections agents viruses most notorious ones. Even in 21st century word, virus creates a panic educated society among professionals. This causes unnecessary havoc, limited help patients malfunctioning The scuffle between humans is unremitting process both continuously changing their combating strategies succeed. Our increasing knowledge about viruses, mechanism rapid involvement novel antiviral techniques has enabled us develop various antivirals. Development very costly, complex, risky, tedious, consuming multistage process. Inspite recent development technology, identification antivirals stern regulation quality control measures; till date there no fool proof (vaccines drugs) available against due viral resistance and/or drug toxicity, rate drugs coming market for application low probably. Therefore, this review mainly based global view discovery including classification antiviral, its developmental stages, current advancements upcoming technologies limitations last five decades future challenges briefly emerging problems healthcare.

参考文章(90)
Samantha Abel, David J Back, Manoli Vourvahis, Maraviroc: pharmacokinetics and drug interactions. Antiviral Therapy. ,vol. 14, pp. 607- 618 ,(2009)
Michael Rowley, The discovery of raltegravir, an integrase inhibitor for the treatment of HIV infection. Progress in Medicinal Chemistry. ,vol. 46, pp. 1- 28 ,(2008) , 10.1016/S0079-6468(07)00001-X
Branko Nikolin, Belma Imamović, Saira Medanhodžić-Vuk, Miroslav Sober, High perfomance liquid chromatography in pharmaceutical analyses. Bosnian Journal of Basic Medical Sciences. ,vol. 4, pp. 5- 9 ,(2004) , 10.17305/BJBMS.2004.3405
PS Jones, Strategies for Antiviral Drug Discovery Antiviral Chemistry & Chemotherapy. ,vol. 9, pp. 1- 20 ,(1998) , 10.1177/095632029800900401
Brian W. J. Mahy, The Dictionary of Virology ,(2008)
Leland J. Gershell, Joshua H. Atkins, A brief history of novel drug discovery technologies Nature Reviews Drug Discovery. ,vol. 2, pp. 321- 327 ,(2003) , 10.1038/NRD1064
Jasper zu Putlitz, Qiao Yu, John M. Burke, Jack R. Wands, Combinatorial Screening and Intracellular Antiviral Activity of Hairpin Ribozymes Directed against Hepatitis B Virus Journal of Virology. ,vol. 73, pp. 5381- 5387 ,(1999) , 10.1128/JVI.73.7.5381-5387.1999
Hugh J Field, Antiviral Chemistry & Chemotherapy's current antiviral agents FactFile 2006 (1st edition). Antiviral Chemistry & Chemotherapy. ,vol. 17, pp. 49- 50 ,(2006) , 10.1177/095632020801900202
Jacques Neefjes, Nico P. Dantuma, Fluorescent probes for proteolysis: tools for drug discovery. Nature Reviews Drug Discovery. ,vol. 3, pp. 58- 69 ,(2004) , 10.1038/NRD1282
M. Murphy, E. Monteiro, Acyclovir-resistant herpes simplex virus infection in HIV-infected patients: a report of three cases and a review of management Journal of The European Academy of Dermatology and Venereology. ,vol. 2, pp. 322- 327 ,(1993) , 10.1111/J.1468-3083.1993.TB00060.X